GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 40.2 Billion KRW | -17.48% |
| 2022 | 48.71 Billion KRW | 25.89% |
| 2021 | 38.7 Billion KRW | -6.75% |
| 2020 | 41.5 Billion KRW | 0.63% |
| 2019 | 41.24 Billion KRW | 20.26% |
| 2018 | 34.29 Billion KRW | 26.21% |
| 2017 | 27.17 Billion KRW | -13.39% |
| 2016 | 31.37 Billion KRW | 10.6% |
| 2015 | 28.36 Billion KRW | 15.19% |
| 2014 | 24.62 Billion KRW | 19.21% |
| 2013 | 20.65 Billion KRW | 6.42% |
| 2012 | 19.41 Billion KRW | -30.02% |
| 2011 | 27.73 Billion KRW | 19.14% |
| 2010 | 23.28 Billion KRW | 55.17% |
| 2009 | 15 Billion KRW | 7.37% |
| 2008 | 13.97 Billion KRW | 38.49% |
| 2007 | 10.09 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 7.03 Billion KRW | -44.87% |
| 2024 Q2 | 9.29 Billion KRW | 32.12% |
| 2023 FY | 40.2 Billion KRW | -17.48% |
| 2023 Q1 | 7.39 Billion KRW | -24.9% |
| 2023 Q2 | 8.32 Billion KRW | 12.64% |
| 2023 Q3 | 11.72 Billion KRW | 40.8% |
| 2023 Q4 | 12.75 Billion KRW | 8.77% |
| 2022 Q2 | 14.38 Billion KRW | 20.55% |
| 2022 Q3 | 12.54 Billion KRW | -12.79% |
| 2022 FY | 48.71 Billion KRW | 25.89% |
| 2022 Q4 | 9.84 Billion KRW | -21.54% |
| 2022 Q1 | 11.93 Billion KRW | 17.01% |
| 2021 Q1 | 9.19 Billion KRW | -23.38% |
| 2021 FY | 38.7 Billion KRW | -6.75% |
| 2021 Q4 | 10.2 Billion KRW | 56.58% |
| 2021 Q2 | 12.79 Billion KRW | 39.13% |
| 2021 Q3 | 6.51 Billion KRW | -49.07% |
| 2020 Q4 | 11.99 Billion KRW | 11.13% |
| 2020 FY | 41.5 Billion KRW | 0.63% |
| 2020 Q3 | 10.79 Billion KRW | 4.66% |
| 2020 Q2 | 10.31 Billion KRW | 22.94% |
| 2020 Q1 | 8.39 Billion KRW | -32.52% |
| 2019 FY | 41.24 Billion KRW | 20.26% |
| 2019 Q1 | 7.38 Billion KRW | -24.38% |
| 2019 Q2 | 10.02 Billion KRW | 35.62% |
| 2019 Q3 | 11.39 Billion KRW | 13.75% |
| 2019 Q4 | 12.43 Billion KRW | 9.09% |
| 2018 Q3 | 8.67 Billion KRW | 5.8% |
| 2018 Q4 | 9.77 Billion KRW | 12.61% |
| 2018 Q2 | 8.2 Billion KRW | 7.28% |
| 2018 Q1 | 7.64 Billion KRW | 21.73% |
| 2018 FY | 34.29 Billion KRW | 26.21% |
| 2017 Q1 | 6.66 Billion KRW | -25.54% |
| 2017 Q3 | 7.67 Billion KRW | 17.27% |
| 2017 Q4 | 6.27 Billion KRW | -18.19% |
| 2017 FY | 27.17 Billion KRW | -13.39% |
| 2017 Q2 | 6.54 Billion KRW | -1.85% |
| 2016 Q4 | 8.95 Billion KRW | 23.1% |
| 2016 FY | 31.37 Billion KRW | 10.6% |
| 2016 Q3 | 7.27 Billion KRW | -7.69% |
| 2016 Q2 | 7.88 Billion KRW | 8.63% |
| 2016 Q1 | 7.25 Billion KRW | 9.95% |
| 2015 Q1 | 6.21 Billion KRW | 37.61% |
| 2015 Q3 | 7.41 Billion KRW | -8.93% |
| 2015 FY | 28.36 Billion KRW | 15.19% |
| 2015 Q4 | 6.59 Billion KRW | -10.99% |
| 2015 Q2 | 8.14 Billion KRW | 31.06% |
| 2014 Q4 | 4.51 Billion KRW | -25.12% |
| 2014 FY | 24.62 Billion KRW | 19.21% |
| 2014 Q3 | 6.02 Billion KRW | -12.64% |
| 2014 Q2 | 6.89 Billion KRW | -3.95% |
| 2014 Q1 | 7.18 Billion KRW | -0.99% |
| 2013 Q2 | 5.22 Billion KRW | 25.39% |
| 2013 Q1 | 4.16 Billion KRW | 2.33% |
| 2013 Q3 | 4 Billion KRW | -23.43% |
| 2013 Q4 | 7.25 Billion KRW | 81.24% |
| 2013 FY | 20.65 Billion KRW | 6.42% |
| 2012 FY | 19.41 Billion KRW | -30.02% |
| 2012 Q2 | 5.04 Billion KRW | 60.68% |
| 2012 Q3 | 5.84 Billion KRW | 15.85% |
| 2012 Q4 | 4.07 Billion KRW | -30.24% |
| 2012 Q1 | 3.13 Billion KRW | 0.0% |
| 2011 Q3 | 5.12 Billion KRW | -10.11% |
| 2011 FY | 27.73 Billion KRW | 19.14% |
| 2011 Q2 | 5.7 Billion KRW | 3.75% |
| 2011 Q1 | 5.49 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | 23.28 Billion KRW | 55.17% |
| 2010 Q3 | 5.92 Billion KRW | 9.58% |
| 2010 Q2 | 5.41 Billion KRW | 85.59% |
| 2010 Q1 | 2.91 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2009 Q2 | 2.73 Billion KRW | -41.39% |
| 2009 Q3 | 3.09 Billion KRW | 13.17% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 15 Billion KRW | 7.37% |
| 2009 Q1 | 4.66 Billion KRW | -23.81% |
| 2008 Q3 | 3.01 Billion KRW | 36.38% |
| 2008 Q4 | 6.11 Billion KRW | 103.19% |
| 2008 FY | 13.97 Billion KRW | 38.49% |
| 2008 Q2 | 2.2 Billion KRW | -16.19% |
| 2008 Q1 | 2.63 Billion KRW | -15.1% |
| 2007 Q4 | 3.1 Billion KRW | 36.7% |
| 2007 Q2 | 2.28 Billion KRW | -6.1% |
| 2007 Q3 | 2.27 Billion KRW | -0.6% |
| 2007 Q1 | 2.43 Billion KRW | 0.0% |
| 2007 FY | 10.09 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -43.556% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | 98.046% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | 97.528% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | 28.499% |
| Green Cross Corporation | 1626.64 Billion KRW | 97.528% |
| Celltrion, Inc. | 2176.43 Billion KRW | 98.153% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 98.912% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | 89.12% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | 88.672% |
| Prestige BioPharma Limited | 689.07 Million KRW | -5734.33% |